Rupee opens flat, may depreciate on strong dollar, risk aversion in markets; USDINR to trade in this range
时间:2024-06-26 12:05:33 阅读(143)
The Indian rupee opened flat on Friday at 82.55 per dollar, up just 1 paise from the previous close. The local unit is likely to depreciate amid a strong dollar and risk aversion in US markets. Rebound in crude prices is also expected to put pressure on the domestic currency. Market sentiments are hurt as strong labour market data reinforced expectations that the Fed may keep rates higher for some time. Also, investors will closely watch non-farm payrolls, average hourly earnings, and ISM Services PMI data to gauge the economic health of the country. “US$INR (January) may hold support near 82.45. As long as its sustains above this level, it may rise back to 82.80 levels,” said ICICI direct.USDINR (spot) to trade positive
“Rupee rose marginally after falling in the last couple of sessions as the dollar retraced in the first half of the session. But the greenback rallied following robust private payrolls number from the US. Private payrolls increased more than expected in December, pointing to still-strong demand for labor despite higher interest rates. US equities fell following the report as investors fear that strong jobs numbers could push the Federal Reserve to keep raising interest rates. Today, the focus will be on the non-farm payrolls number. We expect the USDINR(Spot) to trade positive and quote in the range of 82.50 and 83.05,” said Gaurang Somaiya, Forex & Bullion Analyst, Motilal Oswal Financial Services.
“Dollar selling by Indian exporters has recovered on the back of expectations that the USD has topped out. The average daily dollar sales by exporters beyond the spot date rose about $1.2 billion in November and December month from $900 million levels according to data from the clearing corporation of India and this figure could rise further in Jan month too, which could support the local unit. As the global growth outlook appears gloomier, we believe India’s economic outperformance may continue, which could keep the Rupee in demand. Overall, the view remains the same. The pair is likely to top out near the 83.00 to 83.20 zone. Any rise in the spot market is a good opportunity to sell for exporters. In the near term, it is expected to fall back to 81.50-81.20 levels, where importers can look for hedging,” Amit Pabari, MD, CR Forex Advisors.
Rupee may breach 83 mark in near-term‘The dollar moved little after the FOMC minutes even though the central bank reiterated its focus on getting the multi-decade high inflation under control, and the traders moved their focus on the NFP data. As of now, the Dollar index is stable between the 104.00-104.20 zone. The USDINR pair after breaching above the 83.00 mark has reentered the trading range between 82.50 and 83.00. Today we saw the pair make a move towards the lower end of the range. In the sessions to come, we will carefully observe the price action near the 82.50 zone. On the upside we expect the 83.00-83.20 zone to act as a resistance,” said Anindya Banerjee, VP – Currency Derivatives & Interest Rate Derivatives at Kotak Securities Ltd.
(The recommendations in this story are by the respective research analysts and brokerage firms. FinancialExpress.com does not bear any responsibility for their investment advice. Capital markets investments are subject to rules and regulations. Please consult your investment advisor before investing.)
猜你喜欢
- Sebi seeks higher accountability for REIT, InvIT sponsors
- bi, Daiichi Sankyo has said that going ahead with the open offer at this stage would be “illegal”, “an abuse of process of law”, and “gross overreach” of the pending proceedings before the Delhi High Court and also in violation of the orders of the Supreme Court. The market regulator should, therefore, hear it out before taking any call on the IHH’s proposal, it said.
The Japanese pharma major is also filing a plea before the Delhi HC seeking appointment of forensic auditors to analyse transactions involving IHH, Fortis Healthcare and RHT, Singapore, as directed by the HC on October 18.
The development is likely to create legal hurdles and delay the proposed open offer as IHH had recently told FE that it could only go ahead if Sebi agreed with its legal interpretation that the SC’s September 22 order has lifted all such restraints.
IHH managing director and CEO Kelvin Loh told FE on November 9 that the company would like to go ahead with the open offer “as soon as possible” as there has already been a delay of four years. Ravi Rajagopal, chairman of Fortis Healthcare, had added that their legal counsel has advised that the company can go ahead with the open offer as the SC order has disposed of various appeals, including the suo motu contempt. “We have represented to the Sebi and the matter is with them,” Rajagopal had said.
However, legal observers told FE that the matter is not that straightforward and simple as the Delhi HC has to take the final call on the matter of open offer as well as whether a forensic audit has to be done in the share sale which was executed in 2018.
Also Read: IHH to float open offer for Fortis if Sebi concurs with our legal view: MD & CEO
Loh and Rajagopal had said the possibility that the matter may take a different turn when it comes up in Delhi HC cannot be ruled out.
IHH had in July 2018 acquired a 31% stake in Fortis Healthcare for Rs 4,000 crore through the bidding route. It had also earmarked Rs 3,000 crore to make an open offer for an additional 26% to the public shareholders as required under the law.
Daiichi has written to Sebi that the SC in its September 22 order had asked the HC to consider ordering a forensic audit into the dilution of FHL shareholding, repeated violation of undertakings and assurance by former FHL promoters — Malvinder and Shivinder Singh — and the transaction between FHL, IHH and the clandestine transfer of Rs 4,666 crore to RHT Singapore.
Daiichi is “severely prejudiced” with IHH’s clandestine attempt to subvert the status quo order directed by the SC on December 14, 2018, and September 22 with respect to the conduct of forensic audit and the pending proceedings before the HC by purportedly consulting regulatory authorities, including Sebi, on the proposed FHL-IHH transaction. It has reiterated that the FHL-IHH transaction was currently sub-judice before the HC where FHL is also a party, its solicitors, P&A Law Offices, have said in the letter.
“We further state that any such attempt by FHL and/or IHH to proceed with the FHH-IHH transaction would be in direct contravention of the HC and SC orders,” the letter sent by the law firm has stated. Daiichi Sankyo is pursuing the enforcement of Rs 3,500-crore arbitration award against the Singh brothers pronounced by a Singapore tribunal for concealing information when they sold Ranbaxy Laboratories to it for $4.6 billion in 2008. The apex court had in 2018 put on hold the sale of Fortis Healthcare to IHH on a contempt plea filed by the Japanese drugmaker against the Singh brothers.
- Share Market Highlights- Nifty settles above 19810, Sensex over 66420; Bank Nifty adds over 180 points
- Share Market Highlights- Nifty settles above 17750, Sensex up 70 pts; Bank Nifty above 42650, Adani Ent, Bajaj Finance gain
- Share Market Highlights- Nifty closes below 17050, Sensex tanks 330 pts; Bank Nifty settles below 39450, Adani stocks plunge
- Sensex ends in red for third day running, Nifty support around 15800-16000 levels ahead of F&O expiry tomorrow
- Indian bond yields flattish, Friday’s debt auction to provide cues
- Sebi’s probe can’t go on indefinitely- SAT
- Share Market Highlights- Nifty settles above 17450, Sensex surges 440 pts; Bank Nifty ends above 40650, Adani Ent shares rise 15%